Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Array Biopharma (ARRY) and Clearside Biomedical (CLSD).
Array Biopharma (ARRY)
In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Array Biopharma, with a price target of $23. The company’s shares opened today at $23.53, close to its 52-week high of $23.95.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.1% and a 46.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Array Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $28, representing a 19.0% upside. In a report issued on March 11, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Clearside Biomedical (CLSD)
In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Clearside Biomedical. The company’s shares opened today at $1.32, close to its 52-week low of $0.99.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.5% and a 43.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics Inc, CytomX Therapeutics Inc, and Jounce Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Clearside Biomedical with a $5 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
